10-Q: PACS Group Restates Financials Amid Investigations, CFO Exit

PACS Group restates prior financial statements, reveals material weaknesses in internal controls, and faces multiple government and SEC investigations, alongside a CFO resignation.

Summary

• PACS Group, Inc. has restated its condensed combined/consolidated financial statements for the periods ended March 31, 2024, and June 30, 2024.
• The restatement was due to a reconsideration of revenue recognition for respiratory and certain other therapy services billed under Medicare Part B, and judgmental assessments of compliance.
• An independent Audit Committee investigation, prompted by a short seller report, found that former CFO Derick Apt violated company policies by accepting high-value items from related entities, leading to his resignation.
• Mark Hancock has been appointed as interim Chief Financial Officer.
• Management identified material weaknesses in internal control over financial reporting, specifically regarding an effective control environment and adequate controls within the revenue process for new services.
• Disclosure controls and procedures were deemed not effective as of September 30, 2024.
• The company is implementing a remediation plan, including hiring an Interim Chief Compliance Officer, recruiting additional compliance personnel, forming a Compliance Committee, and enhancing training and revenue recognition controls.
• For the three months ended September 30, 2024, total revenue increased by 30.0% to $1.03 billion, but net income decreased by 18.7% to $16.21 million compared to the same period in 2023.
• For the nine months ended September 30, 2024, total revenue increased by 27.6% to $2.88 billion, but net income decreased by 75.7% to $19.15 million compared to the same period in 2023.
• Operating income for the three months decreased by 36.9% to $22.96 million, and for the nine months decreased by 64.8% to $51.09 million.
• The company is subject to multiple ongoing regulatory investigations by the U.S. Department of Justice (DOJ) related to alleged False Claims Act violations and HIPAA violations.
• The SEC's Division of Enforcement is also conducting an investigation into the company's accounting, financial reporting, disclosure, and internal controls.
• Securities class action and shareholder derivative lawsuits have been filed against the company and its executives, alleging a scheme to inflate revenue and profitability.
• The company entered into forbearance agreements with lenders under its Amended and Restated 2023 Credit Facility due to technical events of default, prohibiting new borrowings during the forbearance period (extended through November 30, 2025).
• PACS Group expanded its operations by adding 46 stand-alone skilled nursing and 22 assisted living facilities during the nine months ended September 30, 2024, and acquired 11 real estate properties for $225.26 million.
• Subsequent to September 30, 2024, the company added 45 stand-alone facilities and acquired five properties for an aggregate purchase price of $138.06 million, while divesting one leased facility.
• The company's founders, Jason Murray and Mark Hancock, collectively beneficially own approximately 70.4% of the voting power of common stock, maintaining substantial control.

Sentiment

Score: 2

Explanation: The filing reveals significant negative events including financial restatements, material weaknesses in internal controls, a CFO resignation due to policy violations, multiple ongoing government and SEC investigations, and class action lawsuits. While revenue grew, net income and EPS declined sharply, and the company is operating under forbearance agreements with lenders. These factors indicate severe operational, financial, and governance challenges, leading to a very negative sentiment.

Positives

• Total revenue increased by 30.0% to $1.03 billion for the three months ended September 30, 2024, and by 27.6% to $2.88 billion for the nine months ended September 30, 2024, compared to the prior year periods.
• Skilled nursing services revenue increased by 28.9% for the three months and 26.9% for the nine months ended September 30, 2024, driven by increased patient days and operational beds.
• The company's operational footprint expanded significantly, with the total number of facilities increasing from 201 to 276 and operational beds from 22,231 to 27,467 from September 30, 2023, to September 30, 2024.
• Average Medicare daily rates increased by 4.5% for the three months and 8.6% for the nine months ended September 30, 2024, partly due to Medicare Part A increases and a higher acuity patient mix.
• Average Medicaid daily rates increased by 4.4% for the three months and 4.2% for the nine months ended September 30, 2024, due to state reimbursement increases and participation in supplemental programs.
• Net cash provided by operating activities for the nine months ended September 30, 2024, increased by $229.4 million to $302.75 million, reflecting improved operational performance and timing of collections.
• The company recognized a bargain purchase gain of $17.19 million from the Prestige acquisition during the nine months ended September 30, 2024.
• The company completed an IPO in April 2024, raising $423.0 million in net proceeds, and a follow-on offering in September 2024, raising $96.4 million in net proceeds, which were used to repay debt and for general corporate purposes.

Negatives

• Net income decreased significantly by 18.7% to $16.21 million for the three months and 75.7% to $19.15 million for the nine months ended September 30, 2024, compared to the prior year periods.
• Operating income declined by 36.9% for the three months and 64.8% for the nine months ended September 30, 2024, indicating increased operating expenses relative to revenue growth.
• Basic net income per share decreased from $0.15 to $0.10 for the three months and from $0.61 to $0.13 for the nine months ended September 30, 2024.
• The company restated previously issued financial statements due to issues with revenue recognition for Medicare Part B services and compliance assessments.
• Material weaknesses in internal control over financial reporting were identified, and disclosure controls and procedures were deemed ineffective.
• The former CFO, Derick Apt, resigned due to violations of company policies, including accepting high-value items from related entities.
• The company is subject to multiple ongoing regulatory investigations by the DOJ and an investigation by the SEC's Division of Enforcement.
• Securities class action and shareholder derivative lawsuits have been filed against the company and its leadership, alleging a scheme to inflate revenue and profitability.
• The company entered into forbearance agreements with its lenders due to technical events of default under its credit facility, which restricts new borrowings and imposes liquidity requirements.
• New facilities experienced a slight decrease in occupancy rate (from 83.4% to 82.8% for three months, and 88.0% to 83.4% for nine months) due to recent acquisitions, which typically have lower initial occupancy.
• Skilled mix by revenue and by nursing patient days for all facilities decreased for the nine months ended September 30, 2024, compared to 2023, indicating a shift towards lower acuity patients or less favorable payor mix.

Risks

• Dependence on reimbursement from third-party payors, with potential negative impacts from changes in patient acuity mix, payor mix, payment methodologies, and cost containment initiatives.
• Risk of not being fully reimbursed for all services billed through consolidated billing or bundled payments.
• Increased competition for, or a shortage of, nurses and other skilled personnel could increase staffing and labor costs and lead to monetary fines.
• State efforts to regulate or deregulate the healthcare services industry could impair expansion or increase competition.
• Failure to attract patients and residents and compete effectively with other healthcare providers could lead to declining revenue and profitability.
• Reviews and audits of care delivery, recordkeeping, and billing processes may detect noncompliance, requiring reduced or repayment of billed amounts.
• Exposure to litigation, which is commonplace in the industry, could result in significant legal costs and large settlement amounts or damage awards.
• Self-insurance programs may expose the company to significant and unexpected costs and losses.
• Material weaknesses in internal control over financial reporting, which, if not effectively remediated, could impair accurate financial reporting and investor confidence.
• Inability to provide consistently high quality of care or employee misconduct could result in civil/criminal penalties, fines, or other adverse actions.
• Significant reliance on information technology, with risks of failure, inadequacy, or interruption harming operations.
• Operational metrics are calculated using internal systems and tools and are not independently verified, potentially leading to inaccuracies that harm reputation.
• Inability to complete future facility or business acquisitions at attractive prices or successfully integrate acquired facilities and properties.
• Adverse impacts from costs, liabilities, and regulatory issues in undertaking acquisitions.
• Difficulty completing partnerships that increase capacity consistent with growth strategy.
• Failure to achieve or maintain competitive quality of care ratings from CMS or private organizations.
• Inability to obtain insurance or increased insurance costs.
• Geographic concentration of facilities (e.g., California) could leave the company vulnerable to economic downturns, regulatory changes, or acts of nature in those areas.
• Actions of national labor unions may adversely affect revenue and profitability.
• Risks associated with leased real property, including lease termination, extensions, and special charges, as the majority of facilities are leased.
• Failure to generate sufficient cash flow to cover required payments or meet operating covenants under long-term debt, mortgages, and long-term leases could result in defaults and cross-defaults.
• Need for additional capital to fund operating subsidiaries and growth, which may not be available on acceptable terms or at all.
• Extensive and complex laws and government regulations, with noncompliance potentially requiring significant expenditures or operational changes.
• Substantial control by founders Jason Murray and Mark Hancock, whose interests may conflict with other stockholders.
• Status as a controlled company, allowing reliance on exemptions from certain NYSE corporate governance standards.
• Volatility or steep decline in the market price of common stock, regardless of operating performance, potentially due to short seller activity or litigation.
• Securities class action litigation and derivative lawsuits could result in substantial costs and divert management attention.
• Inability to comply with NYSE continued listing standards.
• Lack of a sustainable active trading market for common stock.
• Reliance on multiple independent operating subsidiaries for funds, with potential for liabilities of one subsidiary to be imposed on others.
• Future success depends on continuing efforts of management and key employees, and ability to attract and retain highly skilled personnel.
• Changes, reductions, or elimination of coverage or reimbursement for services by third-party payors, including Medicare and Medicaid.
• Increased investigation and enforcement activities related to HIPAA violations.
• Annual caps and other cost reductions for outpatient therapy services may reduce future revenue and profitability.
• Increased investigation and enforcement activities by the Office of the Inspector General (OIG).
• Newly enacted and proposed legislation in states like California may affect operations, increasing costs or imposing new requirements.
• Changes to federal and state employment-related laws and regulations could increase the cost of doing business.
• Required regulatory approvals could delay or prohibit transfers of healthcare operations, leading to periods of unreceived reimbursement.
• Compliance with federal and state fair housing, fire, safety, and other regulations may require unanticipated expenditures.
• Environmental and occupational health and safety regulations could subject the company to fines, penalties, and increased operational costs.
• Future sales, or the perception of future sales, of common stock by existing stockholders could cause the market price to decline.
• If estimates or judgments relating to critical accounting policies are based on incorrect assumptions, operating results could fall below expectations.
• Management team has limited experience managing a public company.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• If securities or industry analysts publish inaccurate or unfavorable research, the trading price or volume of common stock could decline.
• Global economic and financial market conditions, including downturns, could impact business operations and demand.

Future Outlook

The company expects patient and resident service revenue to continue representing the vast majority of total revenue and to increase with the successful execution of its acquisition strategy. Cost of services and rent-cost of services are also expected to increase with business expansion. General and administrative expenses are anticipated to increase on an absolute dollar basis but are expected to be leveraged over time as revenue grows. The company believes its current cash balances and cash flow from operations, along with IPO proceeds, will cover operating needs for at least the next 12 months, but acknowledges that additional capital may be needed for growth and may not be available on favorable terms.

Management Comments

• Management determined that it is appropriate to reconsider the Company’s judgmental assessments of the compliance of its respiratory and certain other therapy services due to regulatory, compliance and Medicare Part B billing uncertainties.
• Management also determined that it is appropriate to reconsider the application of certain aspects of revenue recognition guidance under ASC 606, including with respect to estimating variable consideration and constraining estimated variable consideration related to revenue from billings for such services.
• Management is committed to maintaining a strong internal control environment and is taking comprehensive actions to remediate identified material weaknesses.
• Management believes that the condensed combined/consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented, in accordance with U.S. GAAP, despite material weaknesses.
• We believe our significant historical growth has been primarily driven by our expertise in acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care skilled nursing facilities.
• We are in active discussions with the Required Lenders regarding the terms of an amendment and waiver to our Amended and Restated 2023 Credit Facility and expect to reach an agreement before the end of the forbearance period to be able to borrow additional amounts.

Industry Context

The company operates in the post-acute care industry, which is a large, fragmented market with growing demand driven by an aging population and increasing life expectancies. Skilled Nursing Facilities (SNFs) are an essential, low-cost component of the healthcare continuum. The industry faces stringent regulatory compliance, staffing, and billing requirements, creating acquisition and consolidation opportunities for larger providers. While Medicare and Medicaid reimbursement rates have steadily increased, the regulatory environment is complex and subject to frequent changes, including cost containment efforts and enhanced scrutiny of billing practices. New federal minimum staffing requirements and state-level legislative changes (e.g., California's increased minimum wage for healthcare workers and spending targets) are increasing operational costs and compliance burdens.

Comparison to Industry Standards

• The company's strategy of acquiring underperforming facilities and transforming them into higher-acuity, short-term transitional care facilities is a common approach in the fragmented SNF industry to drive value.
• The average QM Star rating of 4.2 and 95% occupancy for Mature facilities (purchased more than 36 months prior) suggests strong operational performance for established assets, potentially outperforming some industry averages for long-term care facilities.
• The lower QM Star rating of 3.7 and 83% occupancy for New facilities (purchased less than 18 months prior) is consistent with the industry challenge of integrating and improving recently acquired, often underperforming, assets.
• The decline in overall skilled mix by revenue and patient days for the nine-month period, despite an increase in average daily rates, suggests a potential shift in patient mix that could be less favorable compared to industry trends emphasizing higher-acuity care.
• The identification of material weaknesses in internal controls and ongoing regulatory investigations (DOJ, SEC) indicates significant compliance and governance challenges that are more severe than typical industry standards for public companies, potentially impacting investor confidence and operational stability.
• The forbearance agreement with lenders due to technical defaults suggests a higher level of financial distress or operational non-compliance than is standard for healthy public companies in the healthcare sector.

Management Changes

Corporate Governance

Legal Proceedings

• DOJ Civil Investigative Demand (CID) received April 8, 2024, for Providence Administrative Consulting Services and Paradise Valley Healthcare Center, investigating alleged False Claims Act violations and improper patient referrals via Anti-Kickback Statute.
• DOJ CID received September 11, 2024, for California-based skilled nursing facilities, investigating alleged False Claims Act violations related to Medicare reimbursement under the patient-driven payment model (PDPM) and Minimum Data Set Assessments.
• DOJ CID received September 30, 2024, for Providence Group, Inc. and Bishop Care Center, investigating alleged False Claims Act violations related to Medicare reimbursement under the COVID-19 related Hospital Stay Waiver (1135 waiver).
• DOJ subpoena received February 26, 2025, per HIPAA, investigating possible violations of fraudulent or false statements to the U.S. government, including 1135 COVID Waiver practices, Medicare Part B billing for respiratory/sensory integration therapy, insurance enrollment changes, co-pay/deductible waivers, and bad debt reimbursement.
• SEC Investigation by the Division of Enforcement into the company's accounting, financial reporting, disclosure, and internal controls over financial reporting and disclosure controls.
• Securities Class Action (Manchin v. PACS Group, Inc., et al.) filed November 13, 2024, alleging a multi-year scheme to inflate revenue and profitability through exploiting COVID-era Medicare waivers, billing unnecessary Medicare Part B therapies, and falsifying documentation.
• Shareholder Derivative Actions (IN RE PACS GROUP, INC. DERIVATIVE LITIGATION and Boers v. Murray, et. al.) filed February 14, 2025, and August 19, 2025, respectively, alleging breach of fiduciary duties, unjust enrichment, and waste of corporate assets based on similar allegations as the securities class action.
• General litigation, including professional liability claims (personal injury, elder abuse, wrongful death), COVID-19 related claims, and employment-related claims (e.g., wage and hour laws).

Related Party Transactions

• Helios Consulting Agreement with Helios Consulting, LLC (owned by founders Jason Murray and Mark Hancock) was terminated on December 31, 2023. Payments were $0 for the three and nine months ended September 30, 2024, compared to $1,000k and $3,000k for the same periods in 2023.
• Founders Jason Murray and Mark Hancock each purchased 10,000 shares of the company's common stock for $0.001 per share on March 24, 2023.
• Founders Jason Murray and Mark Hancock have provided personal guarantees under certain of the company's leases, subjecting them to increased risk of default.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances, significant uncertainty and potential losses from ongoing legal and regulatory investigations, and limited influence on corporate matters due to concentrated founder control.
• Employees may experience increased scrutiny and changes in compliance procedures due to internal control remediation efforts and regulatory investigations.
• Patients and residents could be impacted by changes in service offerings or billing practices resulting from compliance reassessments and regulatory actions.
• Payors (Medicare, Medicaid, managed care) are directly affected by the company's restatement of revenue recognition and are the focus of several DOJ investigations into billing practices, potentially leading to recoupments or changes in reimbursement.
• Creditors and lenders are impacted by the company's technical events of default and the forbearance agreements, which restrict new borrowings and impose liquidity requirements, indicating increased credit risk.
• Suppliers and vendors may face scrutiny related to related-party transactions and the company's overall financial stability.

Next Steps

• Continue implementing comprehensive actions to remediate identified material weaknesses in internal control over financial reporting.
• Recruit an experienced candidate to serve as the permanent Chief Compliance Officer.
• Recruit additional compliance, legal, and internal audit personnel.
• Oversee a thorough review and approval process for new billing codes prior to billing, and review services under ASC 606 by the accounting function prior to revenue recognition.
• Enhance the Disclosure Committee process by adding sub-certifications and key personnel to address compliance and business activities impacting financial reporting.
• Cooperate with all ongoing regulatory investigations by the DOJ and the SEC.
• Vigorously defend against the securities class action and shareholder derivative lawsuits.
• Engage in active discussions with Required Lenders to reach an amendment and waiver agreement for the Amended and Restated 2023 Credit Facility following the forbearance period.
• Comply with the continued maintenance of minimum liquidity of $100 million and limitations on certain investments and acquisitions during the forbearance period.
• Monitor and respond to potential future inflationary pressures and changes in federal and state healthcare regulations.

Key Dates

Recommendation

The company is facing a confluence of severe negative factors that create extreme uncertainty and risk. The restatement of financial statements, identification of material weaknesses in internal controls, and the ineffectiveness of disclosure controls indicate fundamental flaws in financial reporting and governance. The resignation of the CFO due to policy violations further underscores these issues. Multiple ongoing DOJ and SEC investigations, coupled with securities class action and derivative lawsuits, expose the company to potentially massive legal costs, fines, penalties, and reputational damage, the outcomes of which are currently unquantifiable. While revenue growth is present, the sharp decline in net income and EPS suggests that operational expansion is not translating into sustainable profitability, possibly due to increased costs, compliance issues, or changes in payor mix. The forbearance agreements with lenders due to technical defaults highlight significant financial distress and a constrained ability to access capital. Given these profound and multifaceted challenges, the stock carries an exceptionally high level of risk, making it an unfavorable investment.

Keywords

Skilled Nursing Facilities, Post-Acute Care, Healthcare Services, SEC Filing, Restatement, Internal Controls, Material Weakness, DOJ Investigation, SEC Investigation, False Claims Act, HIPAA, Medicare Part B, Revenue Recognition, Corporate Governance, CFO Resignation, Litigation, Class Action, Shareholder Derivative, Forbearance Agreement, Credit Facility, Acquisitions, Patient Care, Reimbursement, Medicaid, Medicare, Occupancy Rate, Skilled Mix, Financial Performance, Risk Management